Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.25%
1,104.10
+2.73
+0.25%
—1,101.371,103.631,105.311,091.41——
SIXC
Communications
SIXC
Communications
SIXC
-1.50%
604.16
-9.19
-1.50%
—613.35613.35613.35601.49——
SIXE
Energy
SIXE
Energy
SIXE
-0.09%
1,197.81
-1.02
-0.09%
—1,198.831,199.681,199.751,182.41——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,740.41
-15.54
-0.88%
—1,755.951,754.061,756.031,734.69——
SIXM
Financials
SIXM
Financials
SIXM
-0.64%
634.44
-4.07
-0.64%
—638.51637.41637.41633.05——
SIXR
Staples
SIXR
Staples
SIXR
-0.31%
840.90
-2.62
-0.31%
—843.52843.35846.40837.93——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.38%
215.13
-0.82
-0.38%
—215.95215.95216.84215.06——
SIXT
Technology
SIXT
Technology
SIXT
+2.86%
3,228.71
+89.80
+2.86%
—3,138.913,189.303,230.853,174.76——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.16%
935.87
+1.50
+0.16%
—934.37934.72938.26927.50——
SIXV
Health care
SIXV
Health care
SIXV
-1.37%
1,457.12
-20.31
-1.37%
—1,477.431,474.121,474.121,451.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.83%
2,399.84
+19.65
+0.83%
—2,380.192,389.342,403.042,380.47——
CYTK:NASDAQ
Cytokinetics, Inc.
$65.32
-0.24%
(-0.16) 1D
$65.32
0.00% (0.00)
After hours
Closed: Apr 24, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CYTK...
Open
$65.50
High
$65.76
Low
$63.79
Mkt. cap
8.12B
Avg. vol.
1.86M
Volume
967.14K
52-wk high
$70.98
52-wk low
$29.31
EPS
-$6.54
Beta
0.47
Shares outstanding
123.16M
No. of employees
673
News stories
From sources across the web
Profile
Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function. Wikipedia
About Cytokinetics, Inc.
CEORobert I. Blum | Robert I. Blum
Employees673
Founded1997
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websitecytokinetics.com
Next call in 11 days
Tue, May 5, 4:30 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (-1.65 est.)USD
Revenue / Estimate
-/ (9.19M est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earningsInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.58M
66.77M
1.94M
17.76M
Cost of goods sold
99.84M
112.55M
99.23M
104.40M
Cost of revenue
99.84M
112.55M
99.23M
104.40M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
57.37M
65.72M
69.46M
91.72M
Operating expense
57.37M
65.72M
69.46M
91.72M
Total operating expenses
157.21M
178.28M
168.69M
196.12M
Operating income
-155.63M
-111.51M
-166.76M
-178.37M
Other non operating income
3.50M
-11.60M
-123.35M
135.45M
EBT including unusual items
-161.38M
-134.37M
-306.18M
-183.03M
EBT excluding unusual items
-161.38M
-134.37M
-306.18M
-61.78M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-161.38M
-134.37M
-306.18M
-183.03M
Net profit margin
-10,220.14%
-201.25%
-15,814.98%
-1,030.87%
Earnings per share
-1.36
-1.12
-1.54
-1.50
Interest and investment income
13.70M
13.00M
10.25M
11.47M
Interest expense
-22.95M
-24.26M
-26.32M
-30.34M
Net interest expenses
-9.24M
-11.26M
-16.07M
-18.86M
Depreciation and amortization charges
-
-
-
-
EBITDA
-153.33M
-109.22M
-164.08M
-175.50M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer